Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
DANUBE is an open-label, randomised, controlled, phase 3 trial in patients with untreated, unresectable, locally advanced or metastatic urothelial carcinoma. Patients were randomly assigned to receive durvalumab monotherapy, tremelimumab or standard-of-care chemotherapy. Overall survival was compared between the monotherapy and chemotherapy groups.
